Drug Trial Radar · NCT07349524
A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 10, 2026
Primary completion
Mar 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- Reistone Biopharma Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of RSS0343 tablets in patients with COPD. The study includes 3 study periods: a 4-week screening period, a 48-week treatment period, and a 4-week follow-up period. The primary endpoint is the annualized rate of moderate or severe exacerbations of COPD during the 48-week treatment period.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
RSS0343 tabletsDrug
RSS0343 tablets
RSS0343 tablets PlaceboDrug
RSS0343 tablets Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate or severe exacerbations of COPD during the 48-week treatment periodTime frame: during the 48-week treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.